N-(4-methylphenyl)pentamethylenediamine | 1159836-50-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-(4-methylphenyl)pentamethylenediamine
• 英文别名: N'-(4-methoxyphenyl)pentane-1,5-diamine
• CAS: 1159836-50-6
• 化学式: C₁₂H₂₀N₂O
• 分子量: 208.304
• InChiKey: NADNAYMXGMBCMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  47.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-氯代戊酰氯 在 sodium azide 、 diborane(6) 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.75h， 生成 N-(4-methylphenyl)pentamethylenediamine
  参考文献：
  名称：

  N-取代的1，n-二胺的新合成路线。二。由ω-链烷酸衍生物合成选择性N-取代的四亚甲基和五亚甲基二胺

  摘要：

  描述了一种新的合成选择性N-取代的四亚甲基和五亚甲基二胺1（n  = 4,5）的方法。该方法使用N-取代的ω-卤代烷酰胺2作为前体，并涉及微波促进的转化成ω-叠氮羧酰胺3，然后用乙硼烷还原叠氮基和羧酰胺基团。

  DOI：

  10.1016/j.tetlet.2011.01.088

文献信息

• AMINE-DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF
  申请人：OKUNO Takayuki

  公开号：US20100273841A1

  公开（公告）日：2010-10-28

  This invention provides an anorectic or anti-obesity composition comprising a compound of the formula (I): formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted lower alkyl, Y is —S(O)n- wherein n is 1 or 2, or —CO—, R 2 is hydrogen or lower alkyl, R 7 is hydrogen or lower alkyl, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, and Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like.

  本发明提供了一种厌食剂或抗肥胖组合物，包括公式(I)的化合物： 公式(I)： 其药用可接受的盐或溶剂化物， 其中 R1是可选地取代的低级烷基， Y是—S(O)n—，其中n是1或2，或者—CO—， R2是氢或低级烷基， R7是氢或低级烷基， X是低级亚烷基，低级亚烯基，芳基，环烷基或类似物， Z是低级烷基，可选地取代的碳环烷基，可选地取代的杂环烷基或类似物。
• An Efficient Synthesis of <i>N</i>-Arylputrescines and Cadaverines
  作者：Liliana Orelli、Natalia Link、Jimena Díaz

  DOI：10.1055/s-0028-1087817

  日期：——

  We present a two-step, general synthesis of N-aryl­putrescines and cadaverines, by cesium carbonate mediated alkylation of anilines with ω-chloronitriles and subsequent reduction. The cesium-mediated alkylation shows remarkable selectivity towards the monoalkylation product. The method is straightforward and leads to satisfactory global yields.

  我们介绍了一种通过碳酸铯介导的苯胺与Ï-氯腈的烷基化反应以及随后的还原反应，分两步合成 N-芳基putrescines 和adaverines 的通用方法。铯介导的烷基化反应对单烷基化产物具有显著的选择性。该方法简便易行，并能获得令人满意的总产率。
• Amine Derivative Having NPY Y5 Receptor Antagonistic Activity
  申请人：Okuno Takayuki

  公开号：US20100063027A1

  公开（公告）日：2010-03-11

  This invention provides a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted lower alkyl, Y is —S(O) n — wherein n is 1 or 2, or —CO—, R 2 is hydrogen or lower alkyl, R 7 is hydrogen or lower alkyl, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, and Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like.
• AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF
  申请人：OKUNO Takayuki

  公开号：US20100273842A1

  公开（公告）日：2010-10-28

  This invention provides an anorectic or anti-obesity composition comprising a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted lower alkyl, Y is —S(O) n — wherein n is 1 or 2, or —CO—, R 2 is hydrogen or lower alkyl, R 7 is hydrogen or lower alkyl, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, and Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like.
• AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY
  申请人：Okuno Takayuki

  公开号：US20100267945A1

  公开（公告）日：2010-10-21

  A compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, where R 1 is optionally substituted lower alkyl, Y is —S(O) 2 —, R 2 is hydrogen or optionally substituted lower alkyl, R 7 is hydrogen or optionally substituted lower alkyl, X is a group of the formula: where R 5 and R 6 are each independently hydrogen, a group of the formula: is optionally substituted cycloalkylene, p is 0, and q is 1 or 2, Z is optionally substituted carbocyclyl or optionally substituted heterocyclyl, and provided that a compound wherein Z is fused heterocyclyl consisting of three rings or optionally substituted pyrimidinyl is excluded.